Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts rate Theravance Biopharma “Hold” overall: Seven of eight analysts recommend holding the stock, while one gives it a strong-buy rating. The average 12-month price target is $19.40, versus a recent price of $17.04.
• Quarterly results missed expectations: Theravance reported an adjusted loss of $0.11 per share and revenue of $20.73 million, below analyst estimates of $0.07 EPS and $22.49 million in revenue.
• Insiders have been selling shares: Company insiders sold 350,011 shares worth approximately $6.0 million over the past three months, while institutional investors own 99.10% of the stock.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has earned a consensus rating of "Hold" from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $19.40.

Several brokerages have commented on TBPH. Zacks Research upgraded Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 7th. JonesTrading cut Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Monday, June 29th. BTIG Research downgraded shares of Theravance Biopharma from a "buy" rating to a "neutral" rating in a report on Monday, June 29th. Wall Street Zen lowered shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday, May 16th. Finally, Weiss Ratings raised shares of Theravance Biopharma from a "hold (c)" rating to a "hold (c+)" rating in a research note on Monday, August 17th.

Theravance Biopharma Stock Up 0.1%

Shares of TBPH stock opened at $17.04 on Friday. The firm has a market cap of $884.72 million, a P/E ratio of 16.87 and a beta of 0.19. The company has a 50 day moving average of $16.95 and a 200-day moving average of $16.62. Theravance Biopharma has a 12-month low of $13.08 and a 12-month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.18). The firm had revenue of $20.73 million for the quarter, compared to the consensus estimate of $22.49 million. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. As a group, equities analysts expect that Theravance Biopharma will post 1.56 EPS for the current year.

Insider Buying and Selling at Theravance Biopharma

In other news, major shareholder Eli Samaha sold 273,871 shares of the company's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $17.23, for a total value of $4,718,797.33. Following the transaction, the insider owned 9,237,279 shares of the company's stock, valued at approximately $159,158,317.17. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the sale, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. This trade represents a 5.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 350,011 shares of company stock valued at $6,008,309. Insiders own 7.65% of the company's stock.

Institutional Investors Weigh In On Theravance Biopharma

Large investors have recently added to or reduced their stakes in the business. Quarry LP bought a new position in Theravance Biopharma in the 3rd quarter worth about $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company's stock valued at $40,000 after acquiring an additional 1,411 shares in the last quarter. CIBC Private Wealth Group LLC boosted its position in shares of Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 4,662 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after acquiring an additional 781 shares during the last quarter. Finally, Virtus Advisers LLC purchased a new position in shares of Theravance Biopharma during the fourth quarter worth about $170,000. Institutional investors own 99.10% of the company's stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source